<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861130</url>
  </required_header>
  <id_info>
    <org_study_id>13SM0678</org_study_id>
    <nct_id>NCT03861130</nct_id>
  </id_info>
  <brief_title>Genetic Determinants of Kawasaki Disease</brief_title>
  <official_title>Genetic Determinants of Kawasaki Disease for Susceptibility and Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals Bristol NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Great Ormond Street Hospital for Children NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UK Kawasaki Support Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals of North Midlands NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Burton Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>York Teaching Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Shrewsbury and Telford Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>East Suffolk and North Essex NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New Cross Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Darlington Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Torbay Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peterborough City Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals Coventry and Warwickshire NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Tees</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Cornwall Hospitals Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Birmingham Childrenâ€™s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Birmingham Heartlands Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wye Valley NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South Tees Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leeds General Infirmary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bradford Royal Infirmary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals of Morecambe Bay NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Calderdale and Huddersfield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Richard's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pinderfields General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Worthing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Airedale General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sheffield Children's NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwick Park Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West Middlesex Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Albert Edward Infirmary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Macclesfield District General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Oldham Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stepping Hill Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Manchester General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Bolton Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kingston Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tameside Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>East Surrey Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. George's Hospital, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Alexandra Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Kawasaki disease (KD) is an acute self-limited vasculitis of infancy and early childhood.
      Most patients recover without sequelae although the inflammatory process causes permanent
      damage to the coronary arteries in 20-25% of untreated children. An infectious aetiology is
      suspected, but the causative agent has not been identified. The investigators aim to identify
      the genes underlying both susceptibility to Kawasaki disease, and the development of coronary
      artery aneurysms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The problem to be addressed;

      Kawasaki disease is now the most common cause of acquired heart disease in children in Japan
      and North America. Kawasaki disease arises when genetically predisposed children encounter an
      as yet unidentified infectious agent which may cause only mild illness or no illness at all
      in children without the genetic predisposition. Other children may suffer permanent damage to
      the coronary arteries. Identification of the genes involved will help to improve
      understanding of the disease, and the development of better treatments.

      Objective

      The investigators aim to identify the genes underlying both susceptibility to Kawasaki
      disease, and the development of coronary artery aneurysms.

      Design

      The study will recruit nuclear families (affected child and their biological parents) through
      participating NHS hospitals or through the records of the UK Kawasaki Support Group.

      Study size

      400 affected children and both biological parents (i.e. 1200 participants)

      Procedures

      Informed consent using age appropriate patient/parent/guardian information sheets will be
      taken from parents (or from children aged 16 and over), assent will be taken from the child
      under the age of 16 (if appropriate). Children recruited during the acute illness; routine
      clinical and laboratory data and research samples (blood, urine, throat swab). Children
      recruited retrospectively; study questionnaire (completed by parents), saliva samples.Saliva
      samples from parents
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2013</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Susceptibility of coronary artery aneurysms for Kawasaki patients</measure>
    <time_frame>end date; 30 December 2022</time_frame>
    <description>Identification of genes that are associated with susceptibility of coronary artery aneurysms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease severity for Kawasaki patients</measure>
    <time_frame>end date; 30 December 2022</time_frame>
    <description>Identification of genes that are associated with disease severity</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1299</enrollment>
  <condition>Kawasaki Disease</condition>
  <condition>Atypical Kawasaki Disease</condition>
  <arm_group>
    <arm_group_label>Kawasaki disease</arm_group_label>
    <description>Kawasaki disease affected childrens</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA, Paxgene tube, plasma, serum, urine, throat swab, saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children under the care of consultant in hospital for Kawasaki disease, families who are
        members of the UK Kawasaki Support Group
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Affected children will be recruited if the treating clinician has made a diagnosis of
             possible Kawasaki disease (even if they do not fulfil the criteria below for Kawasaki
             disease).

        The current standard diagnostic criteria for KD (Circulation 2001 103 335-336 doi:
        10.1161/01.CIR 103.2.335) are:

        The presence of fever for at least five days plus four of the following criteria:

          1. Changes in the peripheral extremities Acute: erythema and oedema of hands and feet
             Convalescent: membranous desquamation of fingertips

          2. Polymorphous exanthema

          3. Bilateral painless bulbar conjunctival injection without exudate

          4. Changes in lips and oral cavity: erythema and cracking of lips, strawberry tongue,
             diffuse injection of oral and pharyngeal mucosae

          5. Cervical lymphadenopathy (&gt;1.5cm diameter), usually unilateral Patients meeting not
             all of these criteria may meet the criteria for atypical Kawasaki disease, ie. if they
             have fever and two or three of the above criteria and elevation of CRP or
             echocardiographic evidence of coronary artery dilatation.

        Parents of affected child must be biological parents.

        Exclusion Criteria:

          -  children who do not have a diagnosis of possible Kawasaki disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor M Levin</last_name>
    <role>Study Chair</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jethro Herberg</last_name>
    <email>j.herberg@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Galassini</last_name>
    <email>r.galassini@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>London</city>
        <zip>W2 1PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jethro Herberg</last_name>
      <email>j.herberg@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Galassini</last_name>
      <email>r.galassini@imperial.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Levin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Herberg Jethro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>August 16, 2019</last_update_submitted>
  <last_update_submitted_qc>August 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kawasaki Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucocutaneous Lymph Node Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

